CAR-T cell therapy research

Background: Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complicatio…

7566 Background: B-cell maturation antigen (BCMA)–directed therapies have transformed the treatment landscape in RRMM. Belamaf, a BCMA-targeting antibody-drug conjugate, in combination with Pd significantly improved progression-free survival (PFS) vs PVd (hazard ratio [HR], 0.52; 95% CI, 0.37-0.73; P <0.001) in pts wi…

The limited efficacy of current therapeutic options highlights a clear unmet need in patients with digestive neuroendocrine carcinoma. Tarlatamab is a bispecific T-cell engager targeting CD3 on T cells and delta-like ligand 3 on tumor cells. Since delta-like ligand 3 is highly expressed in digestive neuroendocrine car…

Tumor-bearing female miR-146a−/− mouse livers contain increased PD-1+ CD8 T cells and increased aberrant myeloid populations. A, Significantly increased CD8+ T cells were seen in miR-146a−/− livers although no significant change (B) in CD4+ T cells from miR-146a−/− livers was observed. C, Representative flow plots for…

Background/Objectives: Relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) remain a major therapeutic challenge, particularly in patients with aggressive subtypes and limited treatment options after multiple lines of therapy. The ViPOR regimen, a multi-targeted combination of venetoclax, ibrutinib, prednis…

Objective: Hematopoietic stem cell transplantation (HSCT) is a curative treatment for hematological malignancies; however, graft-versus-host disease (GVHD) remains a major complication. While donor T cells are central to GVHD pathogenesis, natural killer (NK) cells, via activating and inhibitory receptors, may also in…

ABSTRACT The investigation by Wu et al. into the synergistic application of interleukin‐15 (IL‐15) and thymosin 1 (T1) marks a pivotal advancement in addressing CD8+ T‐cell immunosenescence within the hepatocellular carcinoma (HCC) microenvironment. By utilizing a clinically relevant aged orthotopic model, the authors…

Background/aim: Targeted therapies with monoclonal antibodies provide cancer patients with better prognosis and disease-free survival. The blockade of immune checkpoints, including programmed cell death protein-1 (PD-1) and its ligand PD-L1, with monoclonal antibodies may boost immune responses against tumors and is r…

Background and Objectives: Comprehensive real-world data on dose-adjusted EPOCH-R (DA-EPOCH-R) incorporating molecular prognostic stratification remain limited. We evaluated the long-term efficacy, safety, and prognostic determinants of DA-EPOCH-R in a multicenter Turkish cohort. Materials and Methods: This retrospect…

Özet henüz yok.

9592 Background: Durability of response and associated long-term survival benefits of modern cancer therapies are often manifested as plateaus in duration of response (DoR) and overall survival (OS) curves for responders. In the single-arm, Phase 2 C-144-01 trial, unresectable/metastatic melanoma patients who progress…

PURPOSE Mantle cell lymphoma (MCL) is a rare and typically aggressive B-cell non-Hodgkin lymphoma characterized by recurrent relapse after short remissions. Sonrotoclax (BGB-11417) is a next-generation B-cell lymphoma 2 inhibitor with greater selectivity and potency than venetoclax, a shorter half-life, and no drug ac…

• MUHİT ÖZCAN